.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The SIROCCO phase 3 trial evaluated benralizumab, an anti-IL-5 receptor monoclonal antibody, in patients with severe uncontrolled asthma despite high-dose inhaled corticosteroid plus LABA therapy and evidence of eosinophilia. More than 1,200 patients were randomized to benralizumab or placebo, with treatment given every four weeks or, after an initial dosing phase, every eight weeks. In patients with elevated blood eosinophils, benralizumab significantly reduced annualized asthma exacerbation rates and improved prebronchodilator FEV1 compared with placebo. The findings helped establish eosinophilic asthma as a clinically actionable phenotype for biologic therapy. For HCPs, the study reinforces a practical sequence: confirm the diagnosis, optimize inhaled treatment and adherence, identify type-2 biomarkers, and then select a biologic for appropriately severe disease. This fits directly with the NAPCON sessions on asthma phenotyping, early biologic therapy and the distinction between eosinophilic and non-eosinophilic disease. The paper is particularly useful for explaining why blood eosinophils can help guide treatment selection, while also emphasizing that biologic choice should be made in the context of the whole clinical picture rather than a single biomarker alone.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The SIROCCO phase 3 trial evaluated benralizumab, an anti-IL-5 receptor monoclonal antibody, in patients with severe uncontrolled asthma despite high-dose inhaled corticosteroid plus LABA therapy and evidence of eosinophilia. More than 1,200 patients were randomized to benralizumab or placebo, with treatment given every four weeks or, after an initial dosing phase, every eight weeks. In patients with elevated blood eosinophils, benralizumab significantly reduced annualized asthma exacerbation rates and improved prebronchodilator FEV1 compared with placebo. The findings helped establish eosinophilic asthma as a clinically actionable phenotype for biologic therapy. For HCPs, the study reinforces a practical sequence: confirm the diagnosis, optimize inhaled treatment and adherence, identify type-2 biomarkers, and then select a biologic for appropriately severe disease. This fits directly with the NAPCON sessions on asthma phenotyping, early biologic therapy and the distinction between eosinophilic and non-eosinophilic disease. The paper is particularly useful for explaining why blood eosinophils can help guide treatment selection, while also emphasizing that biologic choice should be made in the context of the whole clinical picture rather than a single biomarker alone.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
